Cell Cycle & Cancer Biomarkers Group, Cancer Biology Department, Instituto de Investigaciones Biomédicas"Alberto Sols" (IIBm), Consejo Superior de Investigaciones Científicas & Universidad Autónoma de Madrid,(CSIC-UAM), C/Arturo Duperier 4, 28029 Madrid, Spain.
Genes (Basel). 2019 Mar 11;10(3):208. doi: 10.3390/genes10030208.
The master mitotic regulator, Polo-like kinase 1 (Plk1), is an essential gene for the correct execution of cell division. Plk1 has strong clinical relevance, as it is considered a bona fide cancer target, it is found overexpressed in a large collection of different cancer types and this tumoral overexpression often correlates with poor patient prognosis. All these data led the scientific community to historically consider Plk1 as an oncogene. Although there is a collection of scientific reports showing how Plk1 can contribute to tumor progression, recent data from different laboratories using mouse models, show that Plk1 can surprisingly play as a tumor suppressor. Therefore, the fact that Plk1 is an oncogene is now under debate. This review summarizes the proposed mechanisms by which Plk1 can play as an oncogene or as a tumor suppressor, and extrapolates this information to clinical features.
主有丝分裂调节剂 Polo 样激酶 1(Plk1)是细胞分裂正确执行所必需的基因。Plk1 具有很强的临床相关性,因为它被认为是一个真正的癌症靶点,在大量不同的癌症类型中发现过度表达,并且这种肿瘤过度表达通常与患者预后不良相关。所有这些数据导致科学界历史上认为 Plk1 是一种致癌基因。尽管有大量科学报告表明 Plk1 如何促进肿瘤进展,但来自不同实验室的小鼠模型的最新数据表明,Plk1 出人意料地可以作为肿瘤抑制因子发挥作用。因此,Plk1 是否是致癌基因现在存在争议。本综述总结了 Plk1 作为致癌基因或肿瘤抑制因子发挥作用的提出的机制,并将这些信息推断到临床特征。